Latest News and Press Releases
Want to stay updated on the latest news?
-
Yaqrit strengthens leadership team with leading biostatistician, an expert in liver trial design, and renowned US econ/finance strategist joining Board
-
Yaqrit announces eight upcoming presentations at the EASL Congress showcasing progress for drugs and devices in late stage trials in advanced liver disease
-
NIHR grant funds pivotal trial for Yaqrit's liver support device, DIALIVE, with potential to resolve life-threatening condition and impact survival.
-
The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on...
-
NEW YORK, May 27, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Akero Therapeutics, Inc. (NASDAQ: AKRO) between September...
-
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
-
New York, USA, March 25, 2024 (GLOBE NEWSWIRE) -- Cirrhosis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight The rise in the number of people suffering from cirrhosis can be...
-
Dublin, Feb. 21, 2023 (GLOBE NEWSWIRE) -- The "Human Liver Models - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Human Liver...
-
New York, May 04, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Non-Alcoholic Steatohepatitis (NASH) Market Forecast to 2028 - COVID-19 Impact and Global Analysis...
-
Four poster presentations add to the evidence of the beneficial effects of lanifibranor therapy on key components of NASH, following further sub-analyses of Inventiva’s NATIVE Phase IIb clinical trial...